

23rd October, 2019

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,


Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2019

The presentation on unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2019 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: As above



Q2 FY 2019-20

Revenues: Summary



Revenue: Summary

Revenues (Rs crores)	Q2 FY20	Q2 FY19	Gr%	H1 FY20	H1 FY19	Gr%
India	899	815	10%	1,806	1,645	10%
United States	380	394	-3%	757	728	4%
Germany	250	251	-1%	512	503	2%
Brazil	156	147	6%	330	316	4%
Other countries	197	171	15%	376	339	11%
Others (Inc. CRAMS)	123	116	7%	247	236	5%
Total	2,005	1,894	6%	4,027	3,766	7%

